Edition:
United Kingdom

Retrophin Inc (RTRX.OQ)

RTRX.OQ on NASDAQ Stock Exchange Global Market

24.71USD
19 Jan 2018
Change (% chg)

$-0.07 (-0.28%)
Prev Close
$24.78
Open
$24.73
Day's High
$24.81
Day's Low
$24.39
Volume
83,643
Avg. Vol
100,883
52-wk High
$26.43
52-wk Low
$15.57

Latest Key Developments (Source: Significant Developments)

Retrophin Expects Total Net Product Sales Of Approximately $155 Million​ In 2018
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Retrophin Inc ::RETROPHIN PROVIDES CORPORATE UPDATE AND 2018 OUTLOOK.‍FOR FISCAL YEAR 2017, COMPANY EXPECTS TOTAL NET PRODUCT SALES OF APPROXIMATELY $155 MILLION​.‍COMPANY EXPECTS NET PRODUCT SALES FOR Q4 OF 2017 TO BE APPROXIMATELY $42 MILLION​.‍COMPANY EXPECTS A NEW DRUG APPLICATION FILING IN 2018 FOR ITS NEW FORMULATION OF THIOLA FOR TREATMENT OF CYSTINURIA.  Full Article

Retrophin Enters Into Future Acquisition Right, Joint Development Agreement With Censa Pharma
Friday, 5 Jan 2018 

Jan 5 (Reuters) - Retrophin Inc ::RETROPHIN SAYS ON DEC 16, CO ENTERED INTO FUTURE ACQUISITION RIGHT, JOINT DEVELOPMENT AGREEMENT WITH CENSA PHARMA - SEC FILING.RETROPHIN SAYS IF CO EXERCISES OPTION TO BUY CENSA, COMPANY WILL HAVE TO PAY $65 MILLION IN UPFRONT CONSIDERATION.RETROPHIN - ‍AGREED TO FUND CERTAIN DEVELOPMENT ACTIVITIES OF CENSA'S CNSA-001 PROGRAM IN AMOUNT EXPECTED TO BE ABOUT $16 MILLION THROUGH PROOF OF CONCEPT​.RETROPHIN - ALSO ‍HAS RIGHT TO ACQUIRE CENSA ON TERMS AND SUBJECT TO CONDITIONS SET FORTH IN A SEPARATE AGREEMENT AND PLAN OF MERGER​.  Full Article

Retrophin And Censa Pharmaceuticals Enter Into Strategic Collaboration To Advance Cnsa-001
Friday, 5 Jan 2018 

Jan 5 (Reuters) - Retrophin Inc ::RETROPHIN AND CENSA PHARMACEUTICALS ENTER INTO STRATEGIC COLLABORATION TO ADVANCE CNSA-001 FOR THE TREATMENT OF PHENYLKETONURIA (PKU).RETROPHIN INC - ‍UNDER DEAL TERMS , CO IS MAKING A $10 MILLION UPFRONT PAYMENT TO CENSA AND WILL PROVIDE FUNDING FOR DEVELOPMENT OF CNSA-001 IN PKU​.RETROPHIN - UNDER DEAL TERMS, ‍CENSA WILL RUN DEVELOPMENT PROGRAM FOR CNSA-001​, WHICH WILL BE CONDUCTED UNDER OVERSIGHT OF A JOINT STEERING COMMITTEE.  Full Article

Retrophin reports third quarter 2017 financial results
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Retrophin Inc :Retrophin reports third quarter 2017 financial results.Q3 earnings per share view $-0.25 -- Thomson Reuters I/B/E/S.Q3 loss per share $0.46.Q3 adjusted non-GAAP earnings per share $0.15.  Full Article

Retrophin considering acquisition of Raptor Pharmaceutical- Bloomberg
Thursday, 18 Aug 2016 

:Retrophin Inc considering acquisition of Raptor Pharmaceutical Corp - Bloomberg, citing sources.  Full Article

Retrophin posts Q2 adj EPS $0.07, net product sales $33.2 mln
Thursday, 4 Aug 2016 

Retrophin Inc : Q2 adjusted non-gaap earnings per share $0.07 . Q2 revenue rose 38 percent . Retrophin reports second quarter 2016 financial results . Q2 loss per share $0.37 . Retrophin inc says net product sales for q2 of 2016 were $33.3 million, compared to net product sales of $24.1 million for same period in 2015 .Says remains on track to initiate its efficacy trial evaluating RE 024 in pkan during second half of 2016.  Full Article

Martin Shkreli faces June 2017 trial date in fraud case
Thursday, 14 Jul 2016 

: Trial date set by federal judge at hearing in Brooklyn, New York.  Full Article

Retrophin buys liquid formulation of Ursodeoxycholic acid
Monday, 20 Jun 2016 

Retrophin Inc : Made an upfront payment of $0.5 million and will make future payments of up to $23.5 million based on cumulative sales milestones . Intends to file a new drug application with U.S. FDA for liquid formulation of ursodeoxycholic acid in 2017 . Asklepion will be eligible to receive incremental milestone payments of up to $35.0 million upon successful development and commercialization . Will assume all future program costs and pay asklepion tiered royalties on future product sales .Retrophin acquires liquid formulation of ursodeoxycholic acid.  Full Article

Retrophin Inc reiterates FY 2016 revenue guidance
Tuesday, 3 May 2016 

Retrophin Inc:FY 2016 revenue guidance of $130.0 to $140.0 million reiterated.  Full Article

Retrophin Inc board approves $40 mln share repurchase
Tuesday, 3 May 2016 

Retrophin Inc:board of directors has approved repurchase of up to an aggregate $40.0 million of its common stock.  Full Article

BRIEF-Retrophin Expects Total Net Product Sales Of Approximately $155 Million​ In 2018

* ‍FOR FISCAL YEAR 2017, COMPANY EXPECTS TOTAL NET PRODUCT SALES OF APPROXIMATELY $155 MILLION​